To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers
NCT ID: NCT05351840
Last Updated: 2022-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
31 participants
INTERVENTIONAL
2020-11-02
2021-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers
NCT05463497
Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects
NCT05023031
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet
NCT01764178
Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects
NCT05149274
Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects
NCT05141110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period I
Subject will receive Drug(LivaloV), then take it by oral, once-daily form Day 1 to Day 7
LivaloV
Treatment A, Tablet, Oral, QD for 7 Days
Period II
Subject will receive Drug(A), then take it by oral, once-daily form Day 14 to Day 23
A
Treatment B, Tablet, Oral, QD for 10 Days
Period III
Subject will receive Drug(LivaloVA), then take it by oral, once-daily form Day 24 to Day 30
LivaloVA
Treatment C, Tablet, Oral, QD for 7 Days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LivaloV
Treatment A, Tablet, Oral, QD for 7 Days
A
Treatment B, Tablet, Oral, QD for 10 Days
LivaloVA
Treatment C, Tablet, Oral, QD for 7 Days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who are informed of the investigational nature of this study, and voluntarily agree to participate in this study and signs informed consent
Exclusion Criteria
* Subjects who have a medical history and/or condition that is considered to be dangerous to take the study drug.
19 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jang Hee Hong, PI
Role: PRINCIPAL_INVESTIGATOR
Clinical Trial Center, Chungnam National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center, Chungnam National University Hospital
Daejeon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JWP-PVA-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.